SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

Home・Listă Acțiuni・Ipsen SA.

Ipsen SA.

Închisă

SectorFinanțe

165.6 0.67

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

164.5

Maxim

166.2

Indicatori cheie
By Trading Economics
Venit	-225M 110M
Vânzări	36M 1.9B
P/E Medie Sector	30.921 57.736
Randament dividend	0.84
Marjă de profit	5.899
Angajați	5,535
EBITDA	-171M 466M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-12.83% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.84% 4.52%
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.2B 14B
Deschiderea anterioară	164.93
Închiderea anterioară	165.6

Sentimentul știrilor

By Acuity

45%

55%

160 / 439 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

99.85 / 104 Suport & Rezistență

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Achiziții, Fuziuni, Preluări

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Câștiguri

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Achiziții, Fuziuni, Preluări

LVMH to Sell Marc Jacobs

15 mai 2026, 00:00 UTC

Câștiguri

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mai 2026, 23:57 UTC

Achiziții, Fuziuni, Preluări

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Câștiguri

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Câștiguri

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Achiziții, Fuziuni, Preluări

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Câștiguri

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Câștiguri

Nu Holdings 1Q Rev $4.97B >NU

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

-12.83% jos

Prognoză pe 12 luni

Medie 144 EUR -12.83%

Maxim 170 EUR

Minim 130 EUR

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Ipsen SA. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

99.85 / 104Suport & Rezistență

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

160 / 439 Clasament în Finanțe

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.